163 related articles for article (PubMed ID: 1381869)
1. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
3. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
[TBL] [Abstract][Full Text] [Related]
5. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
6. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Fourcade RO
Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
[TBL] [Abstract][Full Text] [Related]
7. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
Tsai YS; Lan SK; Ou JH; Tzai TS
Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
[TBL] [Abstract][Full Text] [Related]
8. [Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
Serment G; Rossi D; Reitz C; Boumendil O
Prog Urol; 2000 Apr; 10(2):254-60. PubMed ID: 10857143
[TBL] [Abstract][Full Text] [Related]
9. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S
Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
[TBL] [Abstract][Full Text] [Related]
11. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
Dunzendorfer U
Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
[TBL] [Abstract][Full Text] [Related]
12. [A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
Kumamoto Y; Yokoyama E; Tsukamoto T; Tsuchida S; Nishizawa O; Koshiba K; Ishibashi A; Ogawa A; Tomita Y; Aso Y
Hinyokika Kiyo; 1987 Oct; 33(10):1681-702. PubMed ID: 2451409
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy--comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker].
Katsumi T; Murayama K
Hinyokika Kiyo; 1992 Sep; 38(9):1089-92. PubMed ID: 1384297
[TBL] [Abstract][Full Text] [Related]
14. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
15. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience: symptomatic management of BPH with terazosin.
Dunzendorfer U
Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
[TBL] [Abstract][Full Text] [Related]
19. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
Low BY; Liong ML; Yuen KH; Chee C; Leong WS; Chong WL; Khan NA; Cheah PY; Liong KK
J Urol; 2008 Apr; 179(4):1461-9. PubMed ID: 18295277
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]